文献速递脑血管病

非维生素K拮抗剂口服抗凝药服药后发生急性缺血性卒中的患者静脉使用tPA

Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
PubMed 文献 · Stroke · 2018-01-01

该文献综述检索2010年1月至2018年3月PubMed,汇总55项研究、492例服用NOAC后接受静脉tPA的急性缺血性卒中患者。观察到症状性颅内出血率4.3%、死亡率11.3%、良好结局率43.7%;达比加群组中tPA前使用依达赛珠单抗逆转与更多良好结局相关,但症状性颅内出血和死亡差异未达统计学显著。

要点

  • 服用NOAC后接受静脉tPA的患者症状性颅内出血率4.3%、死亡率11.3%。
  • 达比加群组使用依达赛珠单抗逆转者良好结局79.1%,未逆转者39.2%。
  • 依达赛珠单抗逆转组症状性颅内出血和死亡差异未达统计学显著。

核心结论

  • 这些初步观察提示,在部分服用NOAC的患者中,tPA可能耐受性尚可,出血并发症风险未达到不可接受的程度。

研究设计与样本

  • 文献综述,检索PubMed从2010年1月至2018年3月,纳入55项研究、492例服用NOAC后接受静脉tPA的患者。

主要发现

  • 在数据完整的患者中,末次NOAC摄入至症状发作的中位时间为8小时(四分位距2.5-14.5),55.2%(80/145)在12小时内。
  • 总体症状性颅内出血率为4.3%(20/462),死亡率为11.3%(48/423),良好结局率为43.7%(164/375)。
  • 达比加群治疗患者中,使用依达赛珠单抗逆转者症状性颅内出血4.5%(2/44) vs 未逆转者7.4%(8/108),未校正比值比0.60(95%CI 0.12-2.92)。
  • 达比加群治疗患者中,使用依达赛珠单抗逆转者死亡4.5%(2/44) vs 未逆转者12.0%(13/108),未校正比值比0.35(95%CI 0.08-1.61)。
  • 达比加群治疗患者中,使用依达赛珠单抗逆转者良好结局79.1%(34/43) vs 未逆转者39.2%(29/74),未校正比值比5.86(95%CI 2.45-14.00)。

临床怎么用

  • 作者认为,这些初步观察提示在部分服用NOAC的患者中tPA可能耐受性尚可。
  • 作者指出,达比加群治疗患者在tPA前使用依达赛珠单抗逆转是一种新兴策略,与更多良好结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Although there are no trials or large cohorts to inform clinical care, current guidelines caution against giving intravenous tPA (tissue-type plasminogen activator) to patients with acute ischemic stroke who are taking non-vitamin K antagonist oral anticoagulants (NOACs). We performed a literature review of intravenous tPA in patients treated with NOACs preceding stroke. Methods- A literature search of PubMed was performed encompassing January 2010 to March 2018. Patient characteristics, timing of last medication intake, laboratory testing, use of reversal, and outcomes ≤3 months after discharge were summarized. Results- We identified 55 studies with 492 NOAC patients receiving tPA (dabigatran, 181; rivaroxaban, 215; apixaban, 40; and unspecified NOAC, 56). Among patients with complete data, the median time from the last NOAC intake to symptom onset was 8 hours (interquartile range, 2.5-14.5), with 55.2% (80/145) within 12 hours. Few patients underwent sensitive laboratory tests, such as thrombin time, diluted thrombin time, or anti-Xa assays before tPA administration. The overall observed rates of symptomatic intracranial hemorrhage, mortality, and favorable outcomes (National Institutes of Health Stroke Scale score, ≤1; modified Rankin Scale score, 0-2; or neurological improvement in the National Institutes of Health Stroke Scale score, ≥8 points) were 4.3% (20/462), 11.3% (48/423), and 43.7% (164/375), respectively. Among dabigatran-treated patients, reversal with idarucizumab was associated with fewer symptomatic intracranial hemorrhage (4.5% [2/44] versus 7.4% [8/108]; unadjusted odds ratio, 0.60; 95% CI, 0.12-2.92), death (4.5% [2/44] versus 12.0% [13/108]; unadjusted odds ratio, 0.35; 95% CI, 0.08-1.61), and more favorable outcomes (79.1% [34/43] versus 39.2% [29/74]; unadjusted odds ratio, 5.86; 95% CI, 2.45-14.00), although the differences were not statistically significant for symptomatic intracranial hemorrhage and death. Conclusions- These preliminary observations suggest that tPA may be reasonably well tolerated without prohibitive risks of bleeding complications in selected patients on NOACs. Reversal of anticoagulant effects by idarucizumab for dabigatran-treated patients before tPA is an emerging strategy that was associated with more favorable outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Jin C, Huang RJ, Peterson ED, et al. Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. Stroke. 2018. PMID: 30354981. doi:10.1161/STROKEAHA.118.022128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。